NO20060466L - Variable antibodies - Google Patents

Variable antibodies

Info

Publication number
NO20060466L
NO20060466L NO20060466A NO20060466A NO20060466L NO 20060466 L NO20060466 L NO 20060466L NO 20060466 A NO20060466 A NO 20060466A NO 20060466 A NO20060466 A NO 20060466A NO 20060466 L NO20060466 L NO 20060466L
Authority
NO
Norway
Prior art keywords
antibodies
factor viii
modified glycosylation
inhibitory
present
Prior art date
Application number
NO20060466A
Other languages
English (en)
Inventor
Jean-Marie Saint-Remy
Marc Jacquemin
Original Assignee
D Collen Res Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0319118A external-priority patent/GB0319118D0/en
Priority claimed from GB0319345A external-priority patent/GB0319345D0/en
Application filed by D Collen Res Foundation Vzw filed Critical D Collen Res Foundation Vzw
Publication of NO20060466L publication Critical patent/NO20060466L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Foreliggende oppfinnelse angår inhibitoriske antistoffer mot faktor VIII med modifisert glykosylering, enten ved enzymatisk deglykosylering eller ved seterettet mutagenese. Nevnte antistoffer med modifisert glykosylering har lik affinitet for FVIII, men viser forskjellige inhiberingsegenskaper. Anvendelsen av en eller en blanding av nevnte antistoffer tillater modulering av inhiberingen av faktor VIII til nivåer mellom 40 og 95 %. Foreliggende oppfinnelse angår videre farmasøytiske preparater omfattende inhibitoriske antistoffer mot faktor VIII med modifisert glykosylering, kombinasjon av disse antistoffer og metoder for behandling av hemostatiske sykdommer ved anvendelse av nevnte antistoffer og antistoffblandinger.
NO20060466A 2003-08-14 2006-01-30 Variable antibodies NO20060466L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0319118A GB0319118D0 (en) 2003-08-14 2003-08-14 Variable antibodies
GB0319345A GB0319345D0 (en) 2003-08-18 2003-08-18 Variable antibodies
PCT/BE2004/000118 WO2005016455A2 (en) 2003-08-14 2004-08-16 Antibodies against factor viii with modified glycosylation in the variable region

Publications (1)

Publication Number Publication Date
NO20060466L true NO20060466L (no) 2006-04-24

Family

ID=34196257

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060466A NO20060466L (no) 2003-08-14 2006-01-30 Variable antibodies

Country Status (9)

Country Link
US (4) US7785594B2 (no)
EP (1) EP1706079B1 (no)
JP (1) JP4934796B2 (no)
AU (1) AU2004264265C1 (no)
CA (1) CA2535489C (no)
ES (1) ES2412489T3 (no)
IL (1) IL173557A (no)
NO (1) NO20060466L (no)
WO (1) WO2005016455A2 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
MXPA05009429A (es) 2003-03-05 2005-12-12 Halozyme Inc Glicoproteina hialuronidasa soluble (shasegp), proceso para preparar la misma, usos y composiciones farmaceuticas que la comprenden.
EP1706079B1 (en) 2003-08-14 2013-02-20 ThromboGenics N.V. Antibodies against factor viii with modified glycosylation in the variable region
FR2897868B1 (fr) 2006-02-24 2012-08-31 Lab Francais Du Fractionnement Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii.
KR101667981B1 (ko) 2006-12-28 2016-10-20 얀센 바이오테크 인코포레이티드 비시알릴화 면역글로불린의 생성 방법 및 생성용 벡터
WO2009024653A1 (fr) * 2007-08-23 2009-02-26 Lfb Biotechnologies Anticorps anti-idiotypigues neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii
KR101915445B1 (ko) * 2007-12-28 2018-11-05 박스알타 인코퍼레이티드 단백질의 역압 여과
US20110117605A1 (en) * 2008-04-23 2011-05-19 Symphogen A/S Methods for Manufacturing a Polyclonal Protein
WO2009154461A1 (en) * 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
EP2233499A1 (en) * 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
MX2012000475A (es) 2009-07-10 2012-03-26 Thrombogenics Nv Variantes de plasminogeno y plasmina.
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EP2480249B1 (en) 2009-08-28 2015-01-28 ThromboGenics N.V. Plasmin for the treatment of filtration failure after trabeculectomy
DK2603528T3 (en) * 2010-08-10 2016-11-28 Glycotope Gmbh FAB-glycosylated ANTIBODIES
EP2661493B1 (en) 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen and plasmin variants
CN102172359A (zh) * 2011-03-02 2011-09-07 张始状 腺苷与核苷组合在制备治疗肿瘤药物中的应用
CN103764163A (zh) 2011-08-12 2014-04-30 斯路姆基因公司 纤溶酶原和纤溶酶变体
EP2785739B1 (en) 2011-12-01 2017-03-15 ThromboGenics N.V. Improving trabeculectomy outcome
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
EP2855529A4 (en) * 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
CA3013808A1 (en) 2016-03-10 2017-09-14 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor
WO2018206734A1 (en) * 2017-05-11 2018-11-15 Vib Vzw Glycosylation of variable immunoglobulin domains
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451454A (en) * 1981-06-16 1984-05-29 Wong Dennis W Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals
IL82935A0 (en) 1986-08-12 1987-12-20 Phillips Petroleum Co Secretion of heterologous proteins from yeast
US5135854A (en) 1987-10-29 1992-08-04 Zymogenetics, Inc. Methods of regulating protein glycosylation
US5602015A (en) * 1989-04-25 1997-02-11 Igen, Inc. Autoantibodies which enhance the rate of a chemical reaction
NZ236491A (en) * 1989-12-18 1993-10-26 Wellcome Found Post-transfusional non-a non-b hepatitis viral polypeptides, dna, antigenic polypeptides and antibodies to the polypeptides
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
ATE198603T1 (de) * 1993-10-25 2001-01-15 Ca Nat Research Council Bivalente thrombininhibitore
IT1277827B1 (it) 1995-03-01 1997-11-12 Ministero Uni Ricerca Scient E Anticorpo monoclonale chimerico murino/umano o un suo frammento specifico per il recettore egf (egf-r)
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
EP1095143B1 (en) 1998-05-08 2008-08-20 Stichting Sanquin Bloedvoorziening Inhibitor for diagnosis and treatment of haemophilia a patients
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE19913707A1 (de) 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
US7067313B1 (en) * 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
EP1194528B1 (en) 1999-07-14 2007-03-07 D. Collen Research Foundation vzw Monoclonal antibody for factor VIII, which even when present in molar excess inactivates factor VIII only in part and a method for producing such an antibody
CA2411323A1 (en) 2000-05-30 2001-12-06 Michael R. Palovich Il-8 receptor antagonists
US6989401B2 (en) 2000-07-19 2006-01-24 Mitsubishi Pharma Corporation Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
ATE468136T1 (de) 2001-01-11 2010-06-15 D Collen Res Foundation Vzw Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion
PT1396539E (pt) 2001-06-12 2009-02-06 Chemo Sero Therapeut Res Inst Anticorpo anti-factor viii da coagulação sanguínea de tipo humano
JP2005538682A (ja) 2001-12-03 2005-12-22 アブジェニックス・インコーポレーテッド カルボキシックアンヒドラーゼｉｘ（ｃａｉｘ）腫瘍抗原に対する抗体
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
EP1706079B1 (en) * 2003-08-14 2013-02-20 ThromboGenics N.V. Antibodies against factor viii with modified glycosylation in the variable region
WO2005046583A2 (en) 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US7858089B2 (en) * 2005-07-29 2010-12-28 Life Sciences Research Partners Vzw Antibodies binding to the A2 domain of FVIII and inhibiting coagulation activity

Also Published As

Publication number Publication date
WO2005016455A2 (en) 2005-02-24
US20100266586A1 (en) 2010-10-21
CA2535489C (en) 2014-09-30
EP1706079B1 (en) 2013-02-20
US20060292149A1 (en) 2006-12-28
AU2004264265A1 (en) 2005-02-24
IL173557A0 (en) 2006-07-05
US8293234B2 (en) 2012-10-23
AU2004264265B2 (en) 2009-09-17
US7785594B2 (en) 2010-08-31
IL173557A (en) 2012-09-24
WO2005016455A3 (en) 2005-03-17
ES2412489T3 (es) 2013-07-11
JP4934796B2 (ja) 2012-05-16
EP1706079A2 (en) 2006-10-04
JP2007502250A (ja) 2007-02-08
US20110070226A1 (en) 2011-03-24
US8282923B2 (en) 2012-10-09
US20100272715A1 (en) 2010-10-28
CA2535489A1 (en) 2005-02-24
US8277805B2 (en) 2012-10-02
AU2004264265C1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
NO20060466L (no) Variable antibodies
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2002036142A3 (en) Compositions for inhibiting grb7
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2006012621A3 (en) Compositions and methods for regulating the alternative pathway of complement
WO2007027559A3 (en) Neuroprotective and neurorestorative methods and compositions
DE602004016499D1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
WO2004031105A3 (en) Use of a33 antigens and jam-it
CY1112875T1 (el) Sfrp και πεπτιδικα μοτιβα που διαντιδρουν με την sfrp και μεθοδοι χρησης τους
WO2002079474A3 (en) Human b7 polypeptides
WO2007067737A3 (en) Methods and compositions for inhibiting hiv infection
WO2006024958A3 (en) Cannabinoid compositions and methods of use thereof
HK1063601A1 (en) Compositions and methods for treating hyperimmune response in the eye
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
DK1196442T3 (da) VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
WO2003038130A3 (en) Therapeutics and diagnostics for disorders of erythropoiesis
WO2005087806A3 (en) Cd38 splice variant and uses thereof
WO2004089302A3 (en) Posh polypeptides, complexes and related methods
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application